B7H3-CAR T / Stanford University - LARVOL DELTA

Single-cell landscape of B7H3-CAR T therapy in glioma: mechanisms of resistance and signatures of long-term response (SNO 2025) - P1 | "This work represents the most comprehensive longitudinal single-cell analysis of CAR T therapy in glioma to date. While we identify a convergent resistance landscape involving myeloid remodeling, Treg infiltration, and target antigen down-regulation, we have also observed long-term survivors with durable tumor control, suggesting that B7H3-CAR T cells can successfully activate endogenous immune responses in select patients. These findings provide a foundation to identify predictive biomarkers distinguishing patients with long-term versus less sustained responses."

Brain Cancer • Glioblastoma • Glioma • High Grade Glioma • Solid Tumor • CD276

Single-cell landscape of B7H3-CAR T therapy in glioma: mechanisms of resistance and signatures of long-term response (SNO 2025) - P1 | "This work represents the most comprehensive longitudinal single-cell analysis of CAR T therapy in glioma to date. While we identify a convergent resistance landscape involving myeloid remodeling, Treg infiltration, and target antigen down-regulation, we have also observed long-term survivors with durable tumor control, suggesting that B7H3-CAR T cells can successfully activate endogenous immune responses in select patients. These findings provide a foundation to identify predictive biomarkers distinguishing patients with long-term versus less sustained responses."

Brain Cancer • Glioblastoma • Glioma • High Grade Glioma • Solid Tumor • CD276

Single-cell landscape of B7H3-CAR T therapy in glioma: mechanisms of resistance and signatures of long-term response (WFNOS 2025) - P1 | "This work represents the most comprehensive longitudinal single-cell analysis of CAR T therapy in glioma to date. While we identify a convergent resistance landscape involving myeloid remodeling, Treg infiltration, and target antigen down-regulation, we have also observed long-term survivors with durable tumor control, suggesting that B7H3-CAR T cells can successfully activate endogenous immune responses in select patients. These findings provide a foundation to identify predictive biomarkers distinguishing patients with long-term versus less sustained responses."

Brain Cancer • Glioblastoma • Glioma • High Grade Glioma • Oncology • Solid Tumor • CD276

Single-cell landscape of B7H3-CAR T therapy in glioma: mechanisms of resistance and signatures of long-term response (WFNOS 2025) - P1 | "This work represents the most comprehensive longitudinal single-cell analysis of CAR T therapy in glioma to date. While we identify a convergent resistance landscape involving myeloid remodeling, Treg infiltration, and target antigen down-regulation, we have also observed long-term survivors with durable tumor control, suggesting that B7H3-CAR T cells can successfully activate endogenous immune responses in select patients. These findings provide a foundation to identify predictive biomarkers distinguishing patients with long-term versus less sustained responses."

Brain Cancer • Glioblastoma • Glioma • High Grade Glioma • Solid Tumor • CD276

Evaluating co-transduction versus a novel bicistronic approach to optimize CAR-T functionality in the context of TGFB-mediated immunosuppression in tumor microenvironment in pediatric solid tumors. (SITC 2025) - "Tumor killing assays are ongoing to evaluate co-transduced versus bicistronic CAR-Ts with a goal to identify the best CAR-T design to translate clinically.Conclusions dnTGFBRII incorporation into B7H3 CAR-Ts resulted in reduced pSMAD immunosuppressive signaling in T cells, maintained cytokine secretion, and improved killing of pediatric solid tumor cell lines. This work will lay the foundation for next-generation CAR-Ts to address immunosuppressive environments of pediatric solid tumors."

Biomarker • Clinical • IO biomarker • Tumor microenvironment • Ewing Sarcoma • Hematological Malignancies • Oncology • Osteosarcoma • Rhabdomyosarcoma • Sarcoma • Solid Tumor • CD276 • IFNG • IL2 • NGFR • TGFB1

B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma Multiforme (clinicaltrials.gov) - P1 | N=39 | Recruiting | Sponsor: Stanford University | Trial completion date: Aug 2025 ➔ Aug 2026 | Trial primary completion date: Aug 2025 ➔ Aug 2026

Trial completion date • Trial primary completion date • Brain Cancer • Glioblastoma • Oncology • Solid Tumor

A phase 1 study of B7H3 CAR-T cells administered intracranially in recurrent glioblastoma. (ASCO 2025) - P1 | "Effective treatments in the recurrent setting following upfront chemoradiation and adjuvant temozolomide are limited...Toxicity otherwise has been primarily related to tumor inflammation-associated neurotoxicity (TIAN), observed after 29 of 36 infusions (81%), and managed acutely with anakinra and dexamethasone... Intracranial administration of B7H3-CART in recurrent GBM is technically feasible and safe. TIAN was common but manageable and reversible with immunomodulators. Correlative analyses on surgical tissue, CSF, and serum are ongoing."

CAR T-Cell Therapy • P1 data • Brain Cancer • CNS Tumor • Glioblastoma • Hypertension • Neutropenia • Oncology • Solid Tumor • Thrombocytopenia • CD276

Parker Institute Showcases Breakthroughs in Immunotherapy at ASCO 2025 as CEO Dr. Karen Knudsen Receives Prestigious Honor (Businesswire) - "As the global oncology community gathers for the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (May 30–June 3), the Parker Institute for Cancer Immunotherapy (PICI) is demonstrating how bold science, accelerated through collaborative networks, can drive meaningful progress where patients need it most....PICI's presence spans more than 50 presentations including 16 oral sessions, 30+ poster sessions, 10 e-papers and a featured clinical science symposium."

Clinical data • Castration-Resistant Prostate Cancer • Glioblastoma • Triple Negative Breast Cancer

B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma Multiforme (clinicaltrials.gov) - P1 | N=39 | Recruiting | Sponsor: Crystal Mackall, MD | Active, not recruiting ➔ Recruiting | N=12 ➔ 39

Enrollment change • Enrollment open • Brain Cancer • Glioblastoma • Oncology • Solid Tumor

B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma Multiforme (clinicaltrials.gov) - P1 | N=12 | Active, not recruiting | Sponsor: Crystal Mackall, MD | Recruiting ➔ Active, not recruiting | N=39 ➔ 12

Enrollment change • Enrollment closed • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor